David Shaw reflects on Creating Ikaria
Ikaria Holdings was formed in 2007 to focus on novel therapy for critically ill patients, with an initial focus on treating hypoxic respiratory failure in newborns via the company’s Inomax product line.
I led the creation of Ikaria Holdings and served as the company’s founding CEO and chair through a time of transformational growth and change. The business combination that created Ikaria Holdings was novel in the biopharmaceutical world, marrying a profitable specialty pharmaceutical company with an early stage drug development company.
The Ikaria team created an amazing success story in the critical care market. It was a pleasure to lead a company with such a motivational life-saving mission, and a culture of intensively caring for patients.